Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes

CompletedOBSERVATIONAL
Enrollment

101

Participants

Timeline

Start Date

September 5, 2019

Primary Completion Date

June 20, 2020

Study Completion Date

June 20, 2020

Conditions
Coronary Artery Disease
Interventions
DIAGNOSTIC_TEST

CardioFlux Magnetocardiography

All patients enrolled and receiving standard screening tests for CAD will undergo a 2 minute scan with MCG. It will be determined if MCG scanning can provide equal or superior accuracy to predict MACE than standard testing.

Trial Locations (1)

26506

J.W. Ruby Memorial Hospital, Morgantown

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genetesis Inc.

INDUSTRY

NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes | Biotech Hunter | Biotech Hunter